Compared with those in the low-risk subgroup, patients with PAAD in the high-risk subgroup exhibited enhanced expression of PDCD1LG2, HAVCR2, CD276, and IDO1 (Figure 10A). Here, HAVCR2 is linked to pancreatic adenocarcinoma.